Clinical Trials Browser

Phase 2/3 × Completed × Multiple Myeloma × Clear all

NCT03357952 2025-02-04

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2/3 Completed

10 enrolled 11 charts

Multiple Myeloma

NCT00177047 2021-11-09

Autologous Transplant for Multiple Myeloma

Phase 2/3 Completed

363 enrolled 25 charts

Multiple Myeloma

NCT00657488 2019-10-18

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase 2/3 Completed

Multiple Myeloma

NCT00038090 2018-10-31

Thalidomide-Dexamethasone for Multiple Myeloma

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02419118 2017-11-07

DARA

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00861250 2016-06-17

Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Phase 2/3 Completed

Multiple Myeloma

NCT00514371 2015-12-07

TIME-2

Phase 2/3 Completed

Multiple Myeloma

NCT00205751 2013-11-25

Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy

Phase 2/3 Completed

Multiple Myeloma

NCT00090493 2013-06-24

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

Phase 2/3 Completed

4 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01085058 2010-03-11

CU01

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

NCT00300664 2006-10-13

A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.

Phase 2/3 Completed

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma